The global biosimilar monoclonal antibodies market is expected to grow at a CAGR of 12.2% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing demand for biosimilars in developed countries and emerging markets such as China and India. The increasing number of patients with chronic diseases such as cancer, autoimmune diseases, and diabetes are also driving the growth of this market.
The global biosimilar monoclonal antibodies market by type includes infliximab, rituximab, trastuzumab, adalimumab. Infliximab is used for treating inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC) and ankylosing spondylitis (AS). Rituximab is used for treating non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Trastuzumab is used for treating breast cancer in women who have received chemotherapy or radiation therapy that has not worked well enough or has stopped working completely. Adalimumab is used for treating rheumatoid arthritis in adults who have not been helped by other treatments or when other treatments cannot be tolerated because they cause too many side effects.
Some Of The Growth Factors Of This Market:
- Increasing awareness about the benefits of biosimilars over their branded counterparts is also expected to drive growth in this market during the forecast period (2017-2025).
- The high cost associated with biologics has been identified as one of the major factors restraining growth in this market globally, which can be attributed to stringent regulations on pricing and reimbursement policies for biologics across various countries worldwide including India and China among others . This factor can be attributed to stringent regulations on pricing and reimbursement policies for biologics across various countries worldwide including India and China among others.
Industry Growth Insights published a new data on “Biosimilar Monoclonal Antibodies Market”. The research report is titled “Biosimilar Monoclonal Antibodies Market research by Types (Infliximab, Rituximab, Trastuzumab, Adalimumab, Other), By Applications (Oncology, Autoimmune Disease, Other), By Players/Companies Celltrion, Pfizer (Hospira), 3SBIO, Novartis (Sandoz), Dr Reddy’s, Celgen Biopharma, Cadila Healthcare, Hisun Pharma, Torrent Pharmaceuticals”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Biosimilar Monoclonal Antibodies Market Research Report
By Type
Infliximab, Rituximab, Trastuzumab, Adalimumab, Other
By Application
Oncology, Autoimmune Disease, Other
By Companies
Celltrion, Pfizer (Hospira), 3SBIO, Novartis (Sandoz), Dr Reddy’s, Celgen Biopharma, Cadila Healthcare, Hisun Pharma, Torrent Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Biosimilar Monoclonal Antibodies Market Report Segments:
The global Biosimilar Monoclonal Antibodies market is segmented on the basis of:
Types
Infliximab, Rituximab, Trastuzumab, Adalimumab, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Autoimmune Disease, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celltrion
- Pfizer (Hospira)
- 3SBIO
- Novartis (Sandoz)
- Dr Reddy’s
- Celgen Biopharma
- Cadila Healthcare
- Hisun Pharma
- Torrent Pharmaceuticals
Highlights of The Biosimilar Monoclonal Antibodies Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Infliximab
- Rituximab
- Trastuzumab
- Adalimumab
- Other
- By Application:
- Oncology
- Autoimmune Disease
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Biosimilar Monoclonal Antibodies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Biosimilar monoclonal antibodies are similar to the original antibody, but they have been produced using different methods. This means that the biosimilar is likely to be less effective and may also have other side effects.
Some of the key players operating in the biosimilar monoclonal antibodies market are Celltrion, Pfizer (Hospira), 3SBIO, Novartis (Sandoz), Dr Reddy¢â‚¬â„¢s, Celgen Biopharma, Cadila Healthcare, Hisun Pharma, Torrent Pharmaceuticals.
The biosimilar monoclonal antibodies market is expected to grow at a compound annual growth rate of 12.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Biosimilar Monoclonal Antibodies Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Biosimilar Monoclonal Antibodies Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Biosimilar Monoclonal Antibodies Market - Supply Chain
4.5. Global Biosimilar Monoclonal Antibodies Market Forecast
4.5.1. Biosimilar Monoclonal Antibodies Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Biosimilar Monoclonal Antibodies Market Size (000 Units) and Y-o-Y Growth
4.5.3. Biosimilar Monoclonal Antibodies Market Absolute $ Opportunity
5. Global Biosimilar Monoclonal Antibodies Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Type
5.3.1. Infliximab
5.3.2. Rituximab
5.3.3. Trastuzumab
5.3.4. Adalimumab
5.3.5. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Biosimilar Monoclonal Antibodies Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Application
6.3.1. Oncology
6.3.2. Autoimmune Disease
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Biosimilar Monoclonal Antibodies Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Biosimilar Monoclonal Antibodies Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Biosimilar Monoclonal Antibodies Demand Share Forecast, 2019-2026
9. North America Biosimilar Monoclonal Antibodies Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Application
9.4.1. Oncology
9.4.2. Autoimmune Disease
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Type
9.7.1. Infliximab
9.7.2. Rituximab
9.7.3. Trastuzumab
9.7.4. Adalimumab
9.7.5. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Biosimilar Monoclonal Antibodies Demand Share Forecast, 2019-2026
10. Latin America Biosimilar Monoclonal Antibodies Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Application
10.4.1. Oncology
10.4.2. Autoimmune Disease
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Type
10.7.1. Infliximab
10.7.2. Rituximab
10.7.3. Trastuzumab
10.7.4. Adalimumab
10.7.5. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Biosimilar Monoclonal Antibodies Demand Share Forecast, 2019-2026
11. Europe Biosimilar Monoclonal Antibodies Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Application
11.4.1. Oncology
11.4.2. Autoimmune Disease
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Type
11.7.1. Infliximab
11.7.2. Rituximab
11.7.3. Trastuzumab
11.7.4. Adalimumab
11.7.5. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Biosimilar Monoclonal Antibodies Demand Share, 2019-2026
12. Asia Pacific Biosimilar Monoclonal Antibodies Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Application
12.4.1. Oncology
12.4.2. Autoimmune Disease
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Type
12.7.1. Infliximab
12.7.2. Rituximab
12.7.3. Trastuzumab
12.7.4. Adalimumab
12.7.5. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Biosimilar Monoclonal Antibodies Demand Share, 2019-2026
13. Middle East & Africa Biosimilar Monoclonal Antibodies Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Application
13.4.1. Oncology
13.4.2. Autoimmune Disease
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Biosimilar Monoclonal Antibodies Market Size and Volume Forecast by Type
13.7.1. Infliximab
13.7.2. Rituximab
13.7.3. Trastuzumab
13.7.4. Adalimumab
13.7.5. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Biosimilar Monoclonal Antibodies Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Biosimilar Monoclonal Antibodies Market: Market Share Analysis
14.2. Biosimilar Monoclonal Antibodies Distributors and Customers
14.3. Biosimilar Monoclonal Antibodies Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Celltrion
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer (Hospira)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. 3SBIO
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis (Sandoz)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Dr Reddys
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Celgen Biopharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Cadila Healthcare
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Hisun Pharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Torrent Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
